Non-profit aims to get COVID-19 field tests, N95 masks and more to healthcare workers without markups

A new Sydney-based non-profit volunteer organization called RapidWard launches this week, with a focus on getting critical medical supplies from producers in China to healthcare professionals, doctors, hospitals and governments worldwide who need them. The group, founded by serial entrepreneur and advisor Milton Zhou, has ample supply chain experience and recognized the need for a solution that focused on establishing distribution pathways that eschew markups in order to make supplies available at-cost.

Zhou, Australian-born founder of Chinese descent who leads Australian sustainable energy company Maoneng as CEO, has been following the coronavirus pandemic and the impact its had in terms of incurring panic buying and hoarding behaviour for much-needed medical equipment. Through existing personal connections, Zhou says that he has access to a factory in China that produces a type of test kit used broadly in that nation’s efforts to combat the spread of COVID-19 (and approved by its equivalent of the FDA).

These kits can produce results in just 15 minutes, using a serological assay that looks for the presence of antibodies in a patient’s bloodstream. This differs from the PCR type of test that is currently in use in the U.S., which looks for the presence of viral DNA in patient mucus samples collected via swab. While the serological test can’t detect COVID-19 during the incubation period, it is reliable once symptoms begin to present, and could help greatly with in-situ diagnostic efforts for patients already presenting with known indicators – freeing up PCR tests for broader use, including asymptomatic screening.

These kits can be provided in volumes of 70,000 per day by RapidWard’s suppliers, the company says, and will be available at the cost of production and shipping of $12 per test. Zhou said that RapidWard is also sourcing lab-free 15-minute saliva-based tests that are in use in both Korea and China, and that can be supplied at a volume of up to 20 units per day.

RapidWard’s supplies also include disposable N95 masks that meet the standards of the FDA and the National Institutes for Occupational Safety and Health, and its partners can produce them (to FDA specs) at a volume of up to 100,000 per day. As with the tests, RapidWard’s focus is on sourcing and supplying these at-cost, without any markups or profits for the organization itself.

Right now, the company is focused on working with and supplying official health organizations and governments in need, but it does have a means for individuals to sign up to register interest, since it plans on offering equipment directly to consumers should supply ever catch up to a point where it’s meeting critical health professional demand and that becomes possible.

RapidWard is encouraging any government or medical institution in need of supplies to get in touch. Even if it can’t provision directly, Zhou says they’re interested in working with these parties to sort out supply chains in China wherever they’re able.

UPS partners with Wingcopter to develop new multipurpose drone delivery fleet

UPS is working with German startup Wingcopter to develop a new type of delivery drone, to be used for the logistics company’s growing commercial drone deliver efforts both in the U.S. and globally. Wingcopter has already designed an electric vertical takeoff and landing (eVTOL) aircraft that have ranges of up to 75 miles, and can achieve speeds as high as 150 miles per hour, in conditions include windspeeds of up to 45 miles per hour.

The two originally entered into a partnership last December, and Wingcopter will be working closely with UPS’ Flight Forward subsidiary, the dedicated drone delivery unit that UPS developed last year in July to house its commercial drone delivery program. In October, Flight Forward received Federal Aviation Administration (FAA) approval to effectively operate a full-scale ‘drone airline’ at scale for the purpose of package delivery.

Wingcopter has already demonstrated how its drones could operate in commercial settings, including during a demonstration with Merck earlier this year that saw its autonomous eVTOLs carry small packages between the drug company’s various office locations in Darmstadt in Germany. It’s also used its aircraft to deliver critical medical supplies and life-saving equipment to hard to reach areas, including through partnerships with UNICEF and other relief organizations.

This collaboration will begin with efforts on behalf of both companies to certify Wingcopter’s aircraft for use in making commercial delivery in the U.S., which will pave the way for collaborative development of additional types of aircraft that will serve a variety of needs, including in industries ranging from healthcare, to hospitality, to retail and more.

Wingcopter’s main advantage is a design that allows it to switch from hovering and vertical lift, to a low-noise forward flight mode, which is better suited to use over populated areas. It manages this using a tilt-rotor design, which has the added benefit of making it more stable in difficult weather conditions, including rain and high winds.

LetsBeatCOVID.net launches to track the spread of the Coronavirus in the UK/US

A startup behind one of the world’s most successful tech platforms for doctors has launched a new initiative to try and track the spread of the Coronavirus, initially in the UK but soon in the US.

Developed by MedShr – the app used by a million doctors to aid them in the diagnostic process – LetsBeatCOVID.net is designed to allow members of the public to complete a short survey about their health and exposure to COVID-19 in order that health services can save more lives.

Members of the public are asked to complete a short anonymous survey about themselves and are able to add information for others in their household or family. They can then update their responses if their situation changes using a randomly generated code to log back in. MedShr says users will, therefore, be able to hide their identity if they are concerned about their privacy. They will, however, be asked to verify their location via the phone’s browser in order to generate more accurate data about the spread of symptoms.
 
Anyone who completes the survey and chooses to enter their email will also get personalized guidance to help them understand their personal situation.

The not-for-profit initiative is led by Dr Asif Qasim, a Consultant Cardiologist based in London, England. Dr Qasim founded MedShr, an online network that enables doctors to connect and share data and knowledge with each other, in 2013.

Dr. Qasim said: “A million doctors around the world are working very hard to protect patients with COVID-19 in difficult and unprecedented circumstances. We are hearing from them that they don’t have the information they need to plan services and avert a crisis such as the one Italy is now facing. We believe this app could help.” Dr. Qasim says the data will be shared with health authorities fighting the pandemic.

LetsBeatCOVID.net could make it easier for members of the public to provide the information urgently needed by hospitals and governments by allowing hospitals to understand how many people are: more likely to require medical help or hospitalization; have been in contact with someone with COVID-19 but do not have any symptoms; have mild symptoms of COVID-19; or believe or know they have already had COVID-19 and recovered.

The spread and devastating impact of Coronavirus (COVID-19) is unprecedented. Hospitals in China and Italy have struggled to care for the large numbers of people who become infected with the virus, especially those who needed Intensive Care and breathing support with a ventilator. Doctors and scientists believe that the UK, US and many other countries could be just a few weeks away from the devastating death toll that Italy is now experiencing. 

MedShr is a HIPAA and GDPR compliant professional network for doctors, nurses and other healthcare professionals currently used by over one million members in 190 countries.

FDA updates COVID-19 testing guidelines to allow self-swab tests

The U.S. Food and Drug Administration (FDA) has updated its guidelines for COVID-19 testing procedures, in a bid to both make the process easier and less uncomfortable for patients, and to help limit the impact of testing on the supply of personal protective equipment (PPE) used by healthcare workers, including protective masks, face shields, gloves and gowns.

The change means that people undertaking a test will be able to conduct their own swab, which will involve swabbing shallowly in their nose. The existing process required a healthcare professional to take the swab, and to collect a sample from further up in the nasal cavity. This change does not mean there’s any difference in the FDA’s guidance regarding at-home sample collection – that is still specifically disallowed by the agency’s rules, something the FDA clarified over the weekend in order to put an end to at-home test collection kits being distributed by diagnostic startups.

Individuals will still have to go to authorized clinical or drive-through testing sites, and will still have to meet the Centers for Disease Control and Prevention (CDC)’s screening requirements in order to get tested in the first place. But Vice President Mike Pence said that this will mean that testing conditions are safer for frontline medical personnel, in addition to lowering the drain on PPE resources.

Pence also added that all state and private labs now required by law to report all of their results by law to the CDC, whereas previously, some states were reporting only positive results, which obviously skewered the data in terms of the number of people in the U.S. tested and the resulting positive diagnoses.

Fiat Chrysler to start producing 1 million face masks a month

Fiat Chrysler Automobiles said Monday it will start manufacturing face masks in the coming weeks and donate the critical medical equipment to first responders and health care workers — the latest automaker to direct its manufacturing expertise towards the COVID-19 pandemic.

The automaker confirmed to TechCrunch that production capacity is being installed this week at one of its factories in China. Manufacturing will start in the coming weeks and distribution will be focused on the U.S., Canada and Mexico. FCA said it plans to produce 1 million face masks a month. All of masks will be donated to police, EMTs and firefighters and workers in hospitals and health care clinics.

“Protecting our first responders and health care workers has never been more important,” FCA CEO Mike Manley said in a statement. “In addition to the support we are giving to increase the production of ventilators, we canvassed our contacts across the healthcare industry and it was very clear that there is an urgent and critical need for face masks. We’ve marshalled the resources of the FCA Group to focus immediately on installing production capacity for making masks and supporting those most in need on the front line of this pandemic.”

The FCA announcement follows a plea last week from Vice President Mike Pence for construction companies to donate their stocks of N95 respirator masks to hospitals. Construction companies have responded, Pence said in a subsequent press conference. Other companies have started donating their caches of face masks as well, including Apple, Facebook, IBM and Tesla.

COVID-19, a disease caused by coronavirus, has led to a shortage of protective equipment such as N-95 respirator masks, gloves and gowns.

Vice President Pence asked construction companies to donate to their local hospitals their stocks of N95 respirator masks and stop ordering more for the time being. This call comes in the middle of a major shortage of these kinds of masks, which get their name from being able to block at least 95% of 0.3 micron particles.

Other manufacturers such as GM, Ford, VW and Tesla have started to work on the complex task of producing ventilators, another critical piece of medical equipment for patients who are hospitalized with COVID-19. The disease attacks the lungs and can cause acute respiratory distress syndrome and pneumonia. And since there is no clinically proven treatment yet, ventilators are relied upon to help people breathe and fight the disease. There are about 160,000 ventilators in the United States and another 12,700 in the National Strategic Supply, the NYT reported.

GM said Friday that it is working with Ventec Life Systems to help increase production of respiratory care products such as ventilators. Tesla CEO Elon Musk said last week that he had a discussion with Medtronic about ventilators. Medtronic later confirmed those talks in a tweet. Musk had previously tweeted that SpaceX and Tesla will work on ventilators, without providing specifics.

Kinsa’s fever map could show just how crucial it is to stay home to stop COVID-19 spread

Smart thermometer maker Kinsa has been working on building, accurate, predictive models of how seasonal illnesses like the flu travel in and among communities – and its fever map is finding new utility as the novel coronavirus pandemic grows globally. While Kinsa’s US Health Weather Map has no way of tracking spread of COVID-19 specifically, since it looks only at fevers tied to geographic data, it could provide easy-to-grasp early indicators of the positive effects of social distancing and isolation measures at the community level.

At the time that Kinsa’s health weather map was covered in the New York Times in February, the company had around a million thermometers in market in the U.S., but it had experienced a significant increase in order volume of as man as 10,000 units per day in the week prior to its publication. That means that the company’s analytics are based on a very large data set relative to the total U.S. population, which Kinsa founder and CEO Inder Singh told me allowed them to achieve an unprecedented level of accuracy and granularity in flu forecasting down to the community level, working in partnership with Oregon State University Assistant Professor Ben Dalziel.

“We showed that the core hypothesis for why I started the company is real – and the core hypothesis was you need real-time, medically accurate, geolocated data that’s taken from people who’ve just fallen ill to detect outbreaks and predict the spread of illness,” Singh said. “What we did with our data is we punched it into Ben’s existing, first-principal models on infectious disease spread. And we were able to show that on September 15, we could predict the entire rest of cold and flu season with hyper-accuracy in terms of the peaks and the valleys – all the way out to the rest of flu season, i.e., 20 weeks out on a hyperlocal basis.”

Prior to this, there have been efforts to track and predict flu transmission, but the “state-of-the-art” to date has been predictions at the national or multi-state level – even trends in individual states, let alone within communities, was out of reach. And in terms of lead time, the best achievable was essentially three weeks out, rather than multiple months, as is possible with Kinsa and Dalziel’s model.

Even without the extraordinary circumstances presented by the global COVID-19 pandemic, what Singh, Dalziel and Kinsa have been able to accomplish is a major step forward in tech-enabled seasonal illness tracking and mitigation. But Kinsa also turned on a feature of their health weather map called ‘atypical illness levels’ a month ago, and that could prove an important leading indicator in shedding more light on the transmission of COVID-19 across the U.S. – and the impact of key mitigation strategies like social distancing.

“We’re taking our real-time illness signal, and we’re subtracting out the expectation,” Singh says, explaining how the new view works. “So what you’re left with is atypical illness. In other words, a cluster of fevers that you would not expect from normal cold and flu time. So, presumably, that is COVID-19; I cannot definitively say it’s COVID-19, but what I can say is that it’s an unusual outbreak. It could be an anomalous flu, a strain that’s totally unexpected. It could be something else, but at least a portion of that is almost certainly going to be COVID-19.”

[gallery ids="1964196,1964197"]

In the example above, Singh says that the spike in fevers coincides with reports of Miami residents and tourists ignoring guidance around recommended distancing. The steep drop-off, however, follows after more extreme measures including beach closures and other isolation tactics were adopted in the area. Singh says that they’re regularly seeing that areas where residents are ignoring social distancing best practices are seeing spikes, and that as soon as those are implemented, via lock-downs and other measures, within five days of those aggressive actions you begin to see downward dips in the curve.

Kinsa’s data has the advantage of being real-time, and continually updated by its users. That provides it a time advantage over other indicators, like the results of increased testing programs for COVID-19, in terms of providing some indication of the more immediate effects of social distancing and isolation strategies. One of the criticisms that has appeared relative to these tactics is that the numbers continue to grow for confirmed cases – but experts expect those cases to grow as we expand the availability of testing and identify new cases of community transmission, even though social distancing is having a positive impact.

As Singh pointed out, Kinsa’s data is strictly about fever-range temperatures, not confirmed COVID-19 cases. But fever is a key and early symptom of COVID-19 in those who are symptomatic, and Kinsa’s existing work on predicting the prevalence of fevers related to cold and flu strongly indicate that what we’re looking at is in fact, at least to a significant degree, COVID-19 spread.

While some have balked at other discussions around using location data to track the spread of the outbreak, Singh says that they’re only interested in two things: geographic coordinates, and temperature. They don’t want any personal identification details that they can tie to either of those signals, so it truly an anonymous aggregation project.

“There is no possible way to reverse engineer a geographic signal to an individual – it’s not possible to do it,” he told me. “This is the right equation to both protect people’s privacy and expose the data that society and communities need.”

For the purposes of tracking atypical illness, Kinsa isn’t currently able to get quite as granular as it is with its standard observed illness map, because it requires a higher degree of sophistication. But the company is eager to expand its dataset with additional thermometers in the market. The Kinsa hardware is already out of stock everywhere, as are most health-related devices, but Singh says they’re pressing ahead with suppliers on sourcing more despite increased component costs across the board. Singh is also eager to work with other smart thermometer makers, either by inputting their data into his model, or by making the Kinsa app compatible with any Bluetooth thermometer that uses the standard connection interface for wireless thermometer hardware.

Currently, Kinsa is working on evolving the atypical illness view to include things like a visual indicator of how fast illness levels are dropping, and how fast they should be dropping in order to effectively break the chain of transmission, as a way to further help inform the public on the impact of their own choices and actions. Despite the widespread agreement by health agencies, researchers and medical professionals, advice to stay home and separated from others definitely presents a challenge for everyone – especially when the official numbers released daily are so dire. Kinsa’s tracker should provide a ray of hope, and a clear sign that each invidious contribution matters.

A new type of COVID-19 test now approved for use could help with frontline diagnostics

The U.S. Food and Drug Administration (FDA) is moving much more quickly to grant special ’emergency use authorization’ to equipment and tests that could help increase testing for the novel coronavirus in the U.S., which lags behind most countries in the world when it comes to tests conducted relative to the size of its population. One type of test just approved for use could help expand the availability of frontline testing in hospitals and at clinics where patients are receiving care – without requiring round-tripping to a dedicated diagnostics lab.

Cepheid’s COVID-19 test, which the agency approved this week, also has the advantage of being able to be run either with or without use of a nasal swab, which is key because supplies of nasal swabs are taxed globally in light of the need for testing. It’s also a molecular, PCR-based test, with high rates of accuracy just like the lab-based testing that’s already in place across facilities in the U.S., but it uses the company’s GeneXpert machine (basically a diagnostics kit the size of an inkjet printer cartdrige lab in a box roughly the size of an inkjet printer) to produce results on-site.

Cepheid says that around 23,000 of its GeneXpert micro-labs are already in use around the world, with around 5,000 of those located in the U.S. The company’s hardware has been running tests for the flu for years already, with high reliability rates. The new COVID-19 tests for the system will begin to be shipped out by the Sunnyvale-based molecular diagnostics company starting next week.

Testing in the U.S. has increased over the past week, thanks in large part to widespread efforts to expand availability especially in hard-hit regions like New York State. But the need for more tests is still pressing, as the limits of availability mean that essentially only the most severe cases, often requiring confirmed contact tracing or proof of elevated risk, are being tested. Solutions like Cepheid’s, as well as other potential alternative test methods than can be done entirely at home, like Scanwell’s forthcoming test that looks for antibodies in a person’s blood, are much-needed if we hope to truly expand testing to a degree that it can properly inform any coronavirus mitigation strategy.

YC startup Felix wants to replace antibiotics with programmable viruses

Right now the world is at war. But this is no ordinary war. It’s a fight with an organism so small we can only detect it through use of a microscope — and if we don’t stop it, it could kill millions of us in the next several decades. No, I’m not talking about COVID-19, though that organism is the one on everyone’s mind right now. I’m talking about antibiotic-resistant bacteria.

You see, more than 700,000 people died globally from bacterial infections last year — 35,000 of them in the U.S. If we do nothing, that number could grow to 10 million annually by 2050, according to a United Nations report.

The problem? Antibiotic overuse at the doctor’s office or in livestock and farming practices. We used a lot of drugs over time to kill off all the bad bacteria — but it only killed off most, not all, of the bad bacteria. And, as the famous line from Jeff Goldblum in Jurassic Park goes, “life finds a way.”

Enter Felix, a biotech startup in the latest Y Combinator batch that thinks it has a novel approach to keeping bacterial infections at bay – viruses.

Phage killing bacteria in a petri dish

It seems weird in a time of widespread concern over the corona virus to be looking at any virus in a good light but as co-founder Robert McBride explains it, Felix’s key technology allows him to target his virus to specific sites on bacteria. This not only kills off the bad bacteria but can also halt its ability to evolve and once more become resistant.

But the idea to use a virus to kill off bacteria is not necessarily new. Bacteriophages, or viruses that can “infect” bacteria, were first discovered by an English researcher in 1915 and commercialized phage therapy began in the U.S. in the 1940’s through Eli Lilly and Company. Right about then antibiotics came along and Western scientists just never seemed to explore the therapy further.

However, with too few new solutions being offered and the standard drug model not working effectively to combat the situation, McBride believes his company can put phage therapy back at the forefront.

Already Felix has tested its solution on an initial group of 10 people to demonstrate its approach.

Felix researcher helping cystic fibrosis patient Ella Balasa through phage therapy

“We can develop therapies in less time and for less money than traditional antibiotics because we are targeting orphan indications and we already know our therapy can work in humans,” McBride told TechCrunch . “We argue that our approach, which re-sensitizes bacteria to traditional antibiotics could be a first line therapy.”

Felix plans to deploy its treatment in those suffering from cystic fibrosis first as there is no cure for this disease, which tends to require a near constant stream of antibiotics to combat lung infections.

The next step will be to conduct a small clinical trial involving 30 people, then, as the scientific research and development model tends to go, a larger human trial before seeking FDA approval. But McBride hopes his viral solution will prove itself out in time to help the coming onslaught of antibiotic resistance.

“We know the antibiotic resistant challenge is large now and is only going to get worse,” McBride said. “We have an elegant technological solution to this challenge and we know our treatment can work. We want to contribute to a future in which these infections do not kill more than 10 million people a year, a future we can get excited about.”

Scanwell aims to launch at-home 15-minute coronavirus test, but it still needs FDA approval

At-home diagnostics startup Scanwell, which produces smartphone-based testing for UTIs, is working on getting at-home testing for the novel coronavirus into the hands of U.S. residents. The technology, which was developed by Chinese diagnostic technology company INNOVITA and has already been approved by China’s equivalent of the FDA and used by “millions” in China, can be taken at home in 15 minutes with the guidance of a medical professional via telehealth, and produces results in just hours.

Scanwell’s test will require FDA clearance, but the company tells me that it’s in the process of securing approval through the FDA’s accelerated emergency certification program. The FDA guidance says that this approval process should take 6-8 weeks (though that “could be faster,” Scanwell says), and Scanwell is aiming to be ready to go with shipping these as soon as it receives that approval. While the U.S. drug regulatory agency previously had only included PCR tests in its protocols, it updated that guidance to include serological tests earlier this week. Scanwell further says they “don’t anticipate any issues with FDA approval.”

The test that Scanwell is aiming to launch uses what’s called a ‘serological’ technique, which looks for antibodies in a patient’s blood. These are only present if someone has been exposed to the SARS-CoV-2 virus, since as of right now researchers haven’t found any evidence that natural antibodies to this particular virus exist without exposure. By contrast, the types of tests that are currently in use in the U.S. are “PCR” tests, which use a molecular-based approach to determine if the virus is present genetically in a mucus sample.

The PCR type of test is technically more accurate than the serological variety, but the serological version is much easier to administer, and produces results more quickly. It’s also still very accurate on the whole, and is much cheaper to produce than the PCR version. Plus, it could help expand efforts beyond testing only the most severe cases with symptoms present, and do a much better job of illuminating the full extent of the presence of the virus, including among people with mild cases who have already recovered at home, and those who are asymptomatic but carrying the virus with the possibility of infecting others.

Also, while other, PCR-based at-home testing options already exist, like one from Everlywell that will start going out on Monday, require round-tripping test samples, adding time, complexity and cost and relying on testing materials like swabs that are in short supply globally.

Once the test is available, people deemed eligible via Scanwell’s screening process in their Scanwell Health app will be sent the test via next-day delivery. They’ll be guided by telehealth partner Lemonade’s licensed doctors and nurse practitioners, and they’ll then receive results and further guidance about those results via the app within a few hours. The whole testing process will cost $70, which Scanwell says just covers its costs (it’s also looking at ways to provide free service to those who need it), and will be deployed first in Washington, California and New York, as well as other areas depending on the severity of their coronavirus situation.

That the tests will take potentially 6-8 weeks to come to market seems like a long time, given the current state of the rapidly evolving COVID-19 situation and testing. But we’ll likely still be very much in need of testing options at that time, especially ones that can serve people who aren’t necessarily meeting the criteria for other available testing resources.

US State Department issues unprecedented ‘do not travel’ warning over coronavirus

The U.S. State Department has issued an unprecedented “do not travel” warning to U.S. citizens, as the number of coronavirus-related infections jumped sharply overnight.

The advisory said U.S. citizens should “avoid all international travel due to the global impact of COVID-19,” the coronavirus strain which last week was declared a global pandemic. The advisory added that citizens abroad should “arrange for immediate return” unless they are prepared to stay overseas indefinitely.

The warning was published Thursday, where the official count for coronavirus cases hit 220,000 infections around the world, with more than 10,000 cases in the United States alone.

Several countries have closed their borders and restricted travel to their citizens and residents in an effort to stem the spread of the virus.

This week, the European Union closed the so-called Schengen border which covers the 27 member state bloc, and the U.S. closed its border with Canada to all but essential travel and trade.

The pandemic has seen stocks and global financial markets tank, prompting governments to inject cash and slash interest rates to try to keep their economies afloat.